Cover Image
市場調查報告書

全球學名藥產業:2016年

Analyzing the Global Generics Industry 2016

出版商 Aruvian's R'search 商品編碼 301382
出版日期 內容資訊 英文 415 Pages
訂單完成後即時交付
價格
Back to Top
全球學名藥產業:2016年 Analyzing the Global Generics Industry 2016
出版日期: 2016年08月01日 內容資訊: 英文 415 Pages
簡介

全球學名藥產業,由於主要藥物的專利到期,及下次的專利到期,而關注高漲。

本報告提供全球學名藥產業調查分析,商業性預測,各地區的競爭情形,主要趨勢和課題等系統性資訊。

A. 摘要整理

B. 全球學名藥產業分析

  • 產業定義
  • 產業的歷史的發展
  • 產業概要
  • 產業規模 (金額、數量) 分析
  • 產業區分:各地區
  • 專利到期
  • 專利到期:各治療領域
  • 全球學名藥產業結構
  • 市場進入
  • 產業上研究開發

C. 全球學名藥產業:波特的五力分析

  • 簡介
  • 買主談判力
  • 供應商談判力
  • 同業者間的競爭
  • 新加入廠商的威脅
  • 替代品的威脅

D. 法律規範和對仿製藥產業的影響

  • 歐洲
  • 日本
  • 美國

E. 產業的趨勢與課題

  • 「支持學名藥」法規的增加
  • 小分子學名藥受歡迎
  • 對生技仿製藥的關注高漲
  • 學名藥的各種未開發市場潛在性
  • 對醫藥品的複數專利保護
  • 製藥創新者企業的生命週期管理策略的課題
  • 研究開發的生產率低

F. 產業策略

  • M&A的增加
  • 有效的外包的利用
  • Hatch-Waxman法和Paragraph IV證明
  • 接受認證的學名藥/複製品的登場
  • 策略性聯盟受歡迎
  • 新興市場存在感

G. 全球學名藥產業:主要市場分析

  • 澳洲
  • 巴西
  • 加拿大
  • 中國
  • 法國
  • 德國
  • 印度
  • 印尼
  • 義大利
  • 日本
  • 墨西哥
  • 荷蘭
  • 新加坡
  • 南非
  • 韓國
  • 西班牙
  • 英國
  • 美國

H. 學名藥的價格與償付:分析 (各主要市場)

  • 概要
  • 澳洲
  • 奧地利
  • 中國
  • 捷克
  • 法國
  • 德國
  • 匈牙利
  • 印度
  • 義大利
  • 日本
  • 挪威
  • 波蘭
  • 羅馬尼亞
  • 西班牙
  • 英國
  • 美國

I. 全球學名藥產業的預測

J. 主要的參與企業

  • Allergan Plc
  • Apotex Inc.
  • Aspen Pharmacare Holdings Ltd
  • Cipla Limited
  • 第一三共
  • Les Laboratoires Servier
  • Lupin Limited
  • Mylan N.V.
  • PT Kalbe Farma Tbk
  • Sanofi SA
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Limited
  • Yuhan Corporation
  • Adcock Ingram Holdings Limited
  • Aurobindo Pharma Limited
  • China Grand Pharmaceutical and Healthcare Holdings Limited
  • EMS Sigma Pharma
  • Esteve Group
  • Eurofarma Laboratorios Ltda
  • O Ache Laboratorios Farmaceuticos SA
  • PT Indofarma (Persero), Tbk
  • PT Sanbe Farma
  • PT Soho Global Health
  • Sandoz International GmbH
  • 澤井製藥
  • Sun Pharmaceutical Industries Ltd.

K. 詞彙表

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global generics industry. Over the years, the global generic drugs industry has grown strongly owing partly to the fact that the period for patent protection has gotten shorter with major blockbuster drugs losing their patent protection.

Furthermore, governments around the world have put in place many policies that are encouraging the growth of generic usage and regulations have also established pricing systems to promote the development of the generic drugs sector.

Aruvian Research analyzes the global generics industry in its research report Analyzing the Global Generics Industry 2016. This in-depth analysis of the global generics industry includes an industry definition, historical development of the industry, industry statistics, value and volume analysis, industry segmentation by geography, amongst others. We analyze the issue of patent expiries by therapeutic areas in details, looking at what the impact is on the generic drugs market. We also look at the industry structure, market entry as well as research & development in the industry. A Porter's Five Forces Strategy analysis of the global generics industry is also included in the report.

The impact of regulatory framework on the generics industry in Europe, Japan and the United States is analyzed in the report, along with the trends and challenges in the global generics industry. We also look at the popularity of small molecule generic drugs as well as the growing focus on biosimilars. Challenge of life cycle management strategies are also looked at. Global generics industry strategies are analyzed as well.

An analysis of major markets is carried out through industry overview, industry value & volume analysis, industry segmentation by geography and an industry forecast. Key markets analyzed include Brazil, Canada, China, France, Germany, India, Italy, Japan, the Netherlands, South Africa, South Korea, Spain, the UK and the United States.

An important aspect of the global generics market is the pricing and reimbursement of generic drugs in major markets. We analyze the pricing and reimbursement in the key markets of Australia, Austria, China, Czech Republic, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Romania, Spain, Sweden, the UK and the United States.

An industry forecast of the global generics industry is included till 2020 through a value and volume forecast.

Major players in the industry are analyzed through a corporate profile, analysis of business segments, major products and services, therapeutic snapshot, financial analysis and a SWOT analysis as well. Major players analyzed in this report include Allergan, Daiichi Sankyo, Lupin, Mylan Inc, Sanofi, STADA Arzneimittel AG, TEVA Pharmaceutical Industries, Apotex, and many others.

Table of Contents

A. Executive Summary

B. Analyzing the Global Generics Industry

  • B.1 Industry Definition
  • B.2 Historical Development of the Industry
  • B.3 Industry Overview
  • B.4 Industry Value & Volume Analysis
  • B.5 Industry Segmentation by Geography
  • B.6 Patent Expiries
  • B.7 Patent Expiries by Therapeutic Areas
  • B.8 Global Generic Industry Structure
  • B.9 Market Entry
  • B.10 Research & Development in the Industry

C. Global Generics Industry: Porter's Five Forces Strategy Analysis

  • C.1 Introduction
  • C.2 Bargaining Power of Buyers
  • C.3 Bargaining Power of Suppliers
  • C.4 Competitive Rivalry in the Industry
  • C.5 Threat of New Entrants
  • C.6 Threat of Substitutes

D. Regulatory Framework & Impact on the Generics Industry

  • D.1 Europe
  • D.2 Japan
  • D.3 United States

E. Industry Trends & Challenges

  • E.1 'Pro-Generics' Legislation on the Rise
  • E.2 Popularity of Small Molecule Generic Drugs
  • E.3 Growing Focus on Biosimilars
  • E.4 Potential in Various Untapped Generics Markets
  • E.5 Multiple Patent Protections on Drugs
  • E.6 Challenge of Life Cycle Management Strategy of Pharma Innovators
  • E.7 Low Research & Development Productivity

F. Industry Strategies

  • F.1 Rise in Mergers & Acquisitions
  • F.2 Effectively Using Outsourcing
  • F.3 Hatch-Waxman Act and Paragraph IV Certifications
  • F.4 Emergence of Authorized Generics/Copies
  • F.5 Popularity of Strategic Alliances
  • F.6 Presence in Emerging Markets

G. Global Generics Industry: Analysis of Major Markets

  • G.1 Australia
    • G.1.1 Industry Overview
    • G.1.2 Industry Value & Volume
    • G.1.3 Industry Segmentation by Geography
    • G.1.4 Industry Forecast
  • G.2 Brazil
    • G.2.1 Industry Overview
    • G.2.2 Industry Value & Volume
    • G.2.3 Industry Segmentation by Geography
    • G.2.4 Industry Forecast
  • G.3 Canada
    • G.3.1 Industry Overview
    • G.3.2 Industry Value & Volume
    • G.3.3 Industry Segmentation by Geography
    • G.3.4 Industry Forecast
  • G.4 China
    • G.4.1 Industry Overview
    • G.4.2 Industry Value & Volume
    • G.4.3 Industry Segmentation by Geography
    • G.4.4 Industry Forecast
  • G.5 France
    • G.5.1 Industry Overview
    • G.5.2 Industry Value & Volume
    • G.5.3 Industry Segmentation by Geography
    • G.5.4 Industry Forecast
  • G.6 Germany
    • G.6.1 Industry Overview
    • G.6.2 Industry Value & Volume
    • G.6.3 Industry Segmentation by Geography
    • G.6.4 Industry Forecast
  • G.7 India
    • G.7.1 Industry Overview
    • G.7.2 Industry Value & Volume
    • G.7.3 Industry Segmentation by Geography
    • G.7.4 Industry Forecast
  • G.8 Indonesia
    • G.8.1 Industry Overview
    • G.8.2 Industry Value & Volume
    • G.8.3 Industry Segmentation by Geography
    • G.8.4 Industry Forecast
  • G.9 Italy
    • G.9.1 Industry Overview
    • G.9.2 Industry Value & Volume
    • G.9.3 Industry Segmentation by Geography
    • G.9.4 Industry Forecast
  • G.10 Japan
    • G.10.1 Industry Overview
    • G.10.2 Industry Value & Volume
    • G.10.3 Industry Segmentation by Geography
    • G.10.4 Industry Forecast
  • G.11 Mexico
    • G.11.1 Industry Overview
    • G.11.2 Industry Value & Volume
    • G.11.3 Industry Segmentation by Geography
    • G.11.4 Industry Forecast
  • G.12 Netherlands
    • G.12.1 Industry Overview
    • G.12.2 Industry Value & Volume
    • G.12.3 Industry Segmentation by Geography
    • G.12.4 Industry Forecast
  • G.13 Singapore
    • G.13.1 Industry Overview
    • G.13.2 Industry Value & Volume
    • G.13.3 Industry Segmentation by Geography
    • G.13.4 Industry Forecast
  • G.14 South Africa
    • G.14.1 Industry Overview
    • G.14.2 Industry Value & Volume
    • G.14.3 Industry Segmentation by Geography
    • G.14.4 Industry Forecast
  • G.15 South Korea
    • G.15.1 Industry Overview
    • G.15.2 Industry Value & Volume
    • G.15.3 Industry Segmentation by Geography
    • G.15.4 Industry Forecast
  • G.16 Spain
    • G.16.1 Industry Overview
    • G.16.2 Industry Value & Volume
    • G.16.3 Industry Segmentation by Geography
    • G.16.4 Industry Forecast
  • G.17 United Kingdom
    • G.17.1 Industry Overview
    • G.17.2 Industry Value & Volume
    • G.17.3 Industry Segmentation by Geography
    • G.17.4 Industry Forecast
  • G.18 United States
    • G.18.1 Industry Overview
    • G.18.2 Industry Value & Volume
    • G.18.3 Industry Segmentation by Geography
    • G.18.4 Industry Forecast

H. Pricing and Reimbursement of Generics: An Analysis by Major Markets

  • H.1 Overview
  • H.2 Pricing & Reimbursement in Australia
    • H.2.1 Overview
    • H.2.2 Generics Pricing & Reimbursement Scenario
    • H.2.3 Trends & Challenges
  • H.3 Pricing & Reimbursement in Austria
    • H.3.1 Overview
    • H.3.2 Generics Pricing & Reimbursement Scenario
    • H.3.3 Trends & Challenges
  • H.4 Pricing & Reimbursement in China
    • H.4.1 Overview
    • H.4.2 Generics Pricing & Reimbursement Scenario
    • H.4.3 Trends & Challenges
  • H.5 Pricing & Reimbursement in the Czech Republic
    • H.5.1 Overview
    • H.5.2 Generics Pricing & Reimbursement Scenario
    • H.5.3 Trends & Challenges
  • H.6 Pricing & Reimbursement in France
    • H.6.1 Overview
    • H.6.2 Generics Pricing & Reimbursement Scenario
    • H.6.3 Trends & Challenges
  • H.7 Pricing & Reimbursement in Germany
    • H.7.1 Overview
    • H.7.2 Generics Pricing & Reimbursement Scenario
    • H.7.3 Trends & Challenges
  • H.8 Pricing & Reimbursement in Hungary
    • H.8.1 Overview
    • H.8.2 Generics Pricing & Reimbursement Scenario
    • H.8.3 Trends & Challenges
  • H.9 Pricing & Reimbursement in India
    • H.9.1 Overview
    • H.9.2 Generics Pricing & Reimbursement Scenario
    • H.9.3 Trends & Challenges
  • H.10 Pricing & Reimbursement in Italy
    • H.10.1 Overview
    • H.10.2 Generics Pricing & Reimbursement Scenario
    • H.10.3 Trends & Challenges
  • H.11 Pricing & Reimbursement in Japan
    • H.11.1 Overview
    • H.11.2 Generics Pricing & Reimbursement Scenario
    • H.11.3 Trends & Challenges
  • H.12 Pricing & Reimbursement in Norway
    • H.12.1 Overview
    • H.12.2 Generics Pricing & Reimbursement Scenario
    • H.12.3 Trends & Challenges
  • H.13 Pricing & Reimbursement in Poland
    • H.13.1 Overview
    • H.13.2 Generics Pricing & Reimbursement Scenario
    • H.13.3 Trends & Challenges
  • H.14 Pricing & Reimbursement in Romania
    • H.14.1 Overview
    • H.14.2 Generics Pricing & Reimbursement Scenario
    • H.14.3 Trends & Challenges
  • H.15 Pricing & Reimbursement in Spain
    • H.15.1 Overview
    • H.15.2 Generics Pricing & Reimbursement Scenario
    • H.15.3 Trends & Challenges
  • H.16 Pricing & Reimbursement in United Kingdom
    • H.16.1 Overview
    • H.16.2 Generics Pricing & Reimbursement Scenario
    • H.16.3 Trends & Challenges
  • H.17 Pricing & Reimbursement in United States
    • H.17.1 Overview
    • H.17.2 Regulation
    • H.17.3 Health Insurance
    • H.17.4 Generics Pricing
    • H.17.5 Reimbursement Scenario
    • H.17.6 Trends & Case Studies
    • H.17.7 Challenges

I. Global Generics Industry Forecast

J. Major Industry Players

  • J.1 Allergan Plc
    • J.1.1 Corporate Analysis
    • J.1.2 Financial Analysis
    • J.1.3 SWOT Analysis
  • J.2 Apotex Inc.
    • J.2.1 Corporate Analysis
    • J.2.2 Financial Analysis
    • J.2.3 SWOT Analysis
  • J.3 Aspen Pharmacare Holdings Ltd
    • J.3.1 Corporate Analysis
    • J.3.2 Financial Analysis
    • J.3.3 SWOT Analysis
  • J.4 Cipla Limited
    • J.4.1 Corporate Analysis
    • J.4.2 Financial Analysis
    • J.4.3 SWOT Analysis
  • J.5 Daiichi Sankyo Co., Ltd.
    • J.5.1 Corporate Analysis
    • J.5.2 Financial Analysis
    • J.5.3 SWOT Analysis
  • J.6 Les Laboratoires Servier
    • J.6.1 Corporate Analysis
    • J.6.2 Financial Analysis
    • J.6.3 SWOT Analysis
  • J.7 Lupin Limited
    • J.7.1 Corporate Analysis
    • J.7.2 Financial Analysis
    • J.7.3 SWOT Analysis
  • J.8 Mylan N.V.
    • J.8.1 Corporate Analysis
    • J.8.2 Financial Analysis
    • J.8.3 SWOT Analysis
  • J.9 PT Kalbe Farma Tbk
    • J.9.1 Corporate Analysis
    • J.9.2 Financial Analysis
    • J.9.3 SWOT Analysis
  • J.10 Sanofi SA
    • J.10.1 Corporate Analysis
    • J.10.2 Financial Analysis
    • J.10.3 SWOT Analysis
  • J.11 STADA Arzneimittel AG
    • J.11.1 Corporate Analysis
    • J.11.2 Financial Analysis
    • J.11.3 SWOT Analysis
  • J.12 Teva Pharmaceutical Industries Limited
    • J.12.1 Corporate Analysis
    • J.12.2 Financial Analysis
    • J.12.3 SWOT Analysis
  • J.13 Yuhan Corporation
    • J.13.1 Corporate Analysis
    • J.13.2 Financial Analysis
    • J.13.3 SWOT Analysis
  • J.14 Adcock Ingram Holdings Limited
  • J.15 Aurobindo Pharma Limited
  • J.16 China Grand Pharmaceutical and Healthcare Holdings Limited
  • J.17 EMS Sigma Pharma
  • J.18 Esteve Group
  • J.19 Eurofarma Laboratórios Ltda
  • J.20 O Aché Laboratórios Farmacêuticos SA
  • J.21 PT Indofarma (Persero), Tbk
  • J.22 PT Sanbe Farma
  • J.23 PT Soho Global Health
  • J.24 Sandoz International GmbH
  • J.25 Sawai Pharmaceutical Company Ltd
  • J.26 Sun Pharmaceutical Industries Ltd.

K. Glossary of Terms

List of Figures

  • Figure 1: Review Process of a Generic Drug
  • Figure 2: Patent Certification Types by ANDA & US FDA Approval Processes
  • Figure 3: Historical Revenues of Leading Generic Companies (in USD Million), 2008-2009
  • Figure 4: Growth of the Global Generics Industry by Value (in USD Billion), 2011-2015
  • Figure 5: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2011-2015
  • Figure 6: Global Generics Market Segmentation by Geography (%), 2015
  • Figure 7: Revenues of Top 10 Drugs that went off Patent between 2010-2014 (in USD Million)
  • Figure 8: Value of Drugs to Lose Patent Protection during 2010-2014 by Therapeutic Area (%)
  • Figure 9: Market Share of Leading Generic Companies Worldwide (%), 2015
  • Figure 10: Comparison of Revenues of Leading Generic Companies (in USD Million), 2013-2014
  • Figure 11: Porter's Five Forces Analysis of the Global Generic Industry
  • Figure 12: Bargaining Power of Buyers in the Global Generic Industry
  • Figure 13: Bargaining Power of Suppliers in the Global Generic Industry
  • Figure 14: Competitive Rivalry in the Global Generic Industry
  • Figure 15: Threat of New Entrants in the Global Generic Industry
  • Figure 16: Threat of Substitutes in the Global Generic Industry
  • Figure 17: Impact of Regulation on the Generics Market in the US
  • Figure 18: ANDA Filings, 2004-2012
  • Figure 19: ANDA Approvals, 2007-2012
  • Figure 20: Market Share of Generics in Selected Countries for Off-Patent Drugs Sector
  • Figure 21: Number of LCM Projects in Late-stage Development by Therapeutic Area, 2014
  • Figure 22: R&D Expenditure and Sales of Leading Pharma Companies (%), 2009-2014
  • Figure 23: Acquisitions by Matrix Labs
  • Figure 24: Region-wise Contribution to Growth of Leading Generic Companies, 2010-2015
  • Figure 25: Healthcare Financing by Selected Countries, 2015
  • Figure 26: Value of the Generics Market in Australia (in USD Million), 2011-2015
  • Figure 27: Volume Growth of the Generics Market in Australia (%), 2011-2015
  • Figure 28: Share of Australia in the Asia Pacific Generics Industry (in USD Billion & %), 2015
  • Figure 29: Forecast of the Generics Market in Australia (in USD Million), 2015-2020
  • Figure 30: Volume Forecast of the Generics Market in Australia (%), 2015-2020
  • Figure 31: Value of the Generics Market in Brazil (in USD Billion), 2011-2015
  • Figure 32: Volume Growth of the Generics Market in Brazil (%), 2011-2015
  • Figure 33: Share of Brazil in the Americas Generics Industry (%), 2015
  • Figure 34: Forecast of the Generics Market in Brazil (in USD Billion), 2015-2020
  • Figure 35: Volume Forecast of the Generics Market in Brazil (%), 2015-2020
  • Figure 36: Value of the Generics Market in Canada (in USD Million), 2011-2015
  • Figure 37: Volume Growth of the Generics Market in Canada (%), 2011-2015
  • Figure 38: Share of Canada in the Americas Generics Industry (%), 2015
  • Figure 39: Forecast of the Generics Market in Canada (in USD Million), 2015-2020
  • Figure 40: Volume Forecast of the Generics Market in Canada (%), 2015-2020
  • Figure 41: Value of the Generics Market in China (in USD Billion), 2011-2015
  • Figure 42: Volume Growth of the Generics Market in China (%), 2011-2015
  • Figure 43: Share of China in the Asia Pacific Generics Industry (%), 2015
  • Figure 44: Forecast of the Generics Market in China (in USD Billion), 2015-2020
  • Figure 45: Volume Forecast of the Generics Market in China (%), 2015-2020
  • Figure 46: Value of the Generics Market in France (in USD Billion), 2011-2015
  • Figure 47: Volume Growth of the Generics Market in France (%), 2011-2015
  • Figure 48: Share of France in the European Generics Industry (%), 2015
  • Figure 49: Forecast of the Generics Market in France (in USD Billion), 2015-2020
  • Figure 50: Volume Forecast of the Generics Market in France (%), 2015-2020
  • Figure 51: Value of the Generics Market in Germany (in USD Billion), 2011-2015
  • Figure 52: Volume Growth of the Generics Market in Germany (%), 2011-2015
  • Figure 53: Share of Germany in the European Generics Industry (%), 2015
  • Figure 54: Forecast of the Generics Market in Germany (in USD Billion), 2015-2020
  • Figure 55: Volume Forecast of the Generics Market in Germany (%), 2015-2020
  • Figure 56: Value of the Generics Market in India (in USD Billion), 2011-2015
  • Figure 57: Volume Growth of the Generics Market in India (%), 2011-2015
  • Figure 58: Share of India in the Asia Pacific Generics Industry (%), 2015
  • Figure 59: Forecast of the Generics Market in India (in USD Billion), 2015-2020
  • Figure 60: Volume Forecast of the Generics Market in India (%), 2015-2020
  • Figure 61: Value of the Generics Market in Indonesia (in USD Billion), 2011-2015
  • Figure 62: Volume Growth of the Generics Market in Indonesia (%), 2011-2015
  • Figure 63: Share of Indonesia in the Asia Pacific Generics Industry (%), 2015
  • Figure 64: Forecast of the Generics Market in Australia (in USD Billion), 2015-2020
  • Figure 65: Volume Forecast of the Generics Market in Indonesia (%), 2015-2020
  • Figure 66: Value of the Generics Market in Italy (in USD Million), 2011-2015
  • Figure 67: Volume Growth of the Generics Market in Italy (%), 2011-2015
  • Figure 68: Share of Italy in the European Generics Industry (%), 2015
  • Figure 69: Forecast of the Generics Market in Italy (in USD Million), 2015-2020
  • Figure 70: Volume Forecast of the Generics Market in Italy (%), 2015-2020
  • Figure 71: Value of the Generics Market in Japan (in USD Billion), 2011-2015
  • Figure 72: Volume Growth of the Generics Market in Japan (%), 2011-2015
  • Figure 73: Share of Japan in the Asia Pacific Generics Industry (%), 2015
  • Figure 74: Forecast of the Generics Market in Japan (in USD Billion), 2015-2020
  • Figure 75: Volume Forecast of the Generics Market in Japan (%), 2015-2020
  • Figure 76: Value of the Generics Market in Mexico (in USD Billion), 2011-2015
  • Figure 77: Volume Growth of the Generics Market in Mexico (%), 2011-2015
  • Figure 78: Share of Mexico in the Americas Generics Industry (%), 2015
  • Figure 79: Forecast of the Generics Market in Mexico (in USD Billion), 2015-2020
  • Figure 80: Volume Forecast of the Generics Market in Mexico (%), 2015-2020
  • Figure 81: Value of the Generics Market in the Netherlands (in USD Million), 2011-2015
  • Figure 82: Volume Growth of the Generics Market in the Netherlands (%), 2011-2015
  • Figure 83: Share of Netherlands in the European Generics Industry (%), 2015
  • Figure 84: Forecast of the Generics Market in the Netherlands (in USD Million), 2015-2020
  • Figure 85: Volume Forecast of the Generics Market in the Netherlands (%), 2015-2020
  • Figure 86: Value of the Generics Market in Singapore (in USD Million), 2011-2015
  • Figure 87 : Volume Growth of the Generics Market in Singapore (%), 2011-2015
  • Figure 88: Share of Singapore in the Asia Pacific Generics Industry (%), 2015
  • Figure 89: Forecast of the Generics Market in Singapore (in USD Million), 2015-2020
  • Figure 90: Volume Forecast of the Generics Market in Singapore (%), 2015-2020
  • Figure 91: Value of the Generics Market in South Africa (in USD Million), 2011-2015
  • Figure 92: Volume Growth of the Generics Market in South Africa (%), 2011-2015
  • Figure 93: Share of South Africa in the MEA Generics Industry (%), 2015
  • Figure 94: Forecast of the Generics Market in South Africa (in USD Million), 2015-2020
  • Figure 95: Volume Forecast of the Generics Market in South Africa (%), 2015-2020
  • Figure 96: Value of the Generics Market in South Korea (in USD Billion), 2011-2015
  • Figure 97: Volume Growth of the Generics Market in South Korea (%), 2011-2015
  • Figure 98: Share of South Korea in the Asia Pacific Generics Industry (%), 2015
  • Figure 99: Forecast of the Generics Market in South Korea (in USD Billion), 2015-2020
  • Figure 100: Volume Forecast of the Generics Market in South Korea (%), 2015-2020
  • Figure 101: Value of the Generics Market in Spain (in USD Billion), 2011-2015
  • Figure 102: Volume Growth of the Generics Market in Spain (%), 2011-2015
  • Figure 103: Share of Spain in the European Generics Industry (%), 2015
  • Figure 104: Forecast of the Generics Market in Spain (in USD Billion), 2015-2020
  • Figure 105: Volume Forecast of the Generics Market in Spain (%), 2015-2020
  • Figure 106: Value of the Generics Market in the UK (in USD Billion), 2011-2015
  • Figure 107: Volume Growth of the Generics Market in the UK (%), 2011-2015
  • Figure 108: Share of the UK in the European Generics Industry (%), 2015
  • Figure 109: Forecast of the Generics Market in the UK (in USD Billion), 2015-2020
  • Figure 110: Volume Forecast of the Generics Market in the UK (%), 2015-2020
  • Figure 111: Value of the Generics Market in the US (in USD Billion), 2011-2015
  • Figure 112: Volume Growth of the Generics Market in the US (%), 2011-2015
  • Figure 113: Share of the US in the Global Generics Industry (%), 2015
  • Figure 114: Forecast of the Generics Market in the US (in USD Billion), 2015-2020
  • Figure 115: Volume Forecast of the Generics Market in the US (%), 2015-2020
  • Figure 116: Healthcare Regulatory Agencies in China & their Responsibilities
  • Figure 117: Financing Law of Social Security (Loi de Financement de la Sécurité Sociale) in France
  • Figure 118: Impacts on Drug Prices in India
  • Figure 119: Stepped Price System in Norway
  • Figure 120: Distribution Channel and Logistics of Generics in the US
  • Figure 121: Fee for Service, Preferred Provider Organization & Health Maintenance Organization in the US
  • Figure 122: Standard Medicare Part D Benefit Comparison of 2011 & 2020 in the US
  • Figure 123: Global Generics Industry Forecast (in USD Billion), 2015-2020
  • Figure 124: Global Generics Industry Forecast by Volume (% of Pharma Volume), 2015-2020
  • Figure 125: Revenues & Profitability of Allergan Plc (in USD Million), 2010-2014
  • Figure 126: Revenues & Profitability of Aspen Pharmacare (in USD Million), 2011-2015
  • Figure 127: Revenues & Profitability of Cipla Limited (in USD Million), 2011-2015
  • Figure 128: Revenues & Profitability of Daiichi Sankyo (in USD Million), 2011-2015
  • Figure 129: Revenues & Profitability of Lupin (in USD Million), 2011-2015
  • Figure 130: Revenues & Profitability of Mylan (in USD Million), 2010-2014
  • Figure 131: Revenues & Profitability of PT Kalbe Farma Tbk (in USD Million), 2010-2014
  • Figure 132: Revenues & Profitability of Sanofi SA (in USD Million), 2010-2014
  • Figure 133: Revenues & Profitability of STADA Arzneimittel AG (in USD Million), 2010-2014
  • Figure 134: Revenues & Profitability of Teva Pharmaceutical (in USD Million), 2010-2014
  • Figure 135: Revenues & Profitability of Yuhan Corporation (in USD Million), 2010-2014
  • Figure 136: Revenues & Profitability of Adcock Ingram (in USD Million), 2010-2014
  • Figure 137: Revenues & Profitability of Aurobindo Pharma (in USD Million), 2011-2015
  • Figure 138: Revenues & Profitability of China Grand Pharmaceutical and Healthcare (in USD Million), 2010-2014
  • Figure 139: Revenues & Profitability of PT Indofarma (Persero) (in USD Million), 2010-2014
  • Figure 140: Revenues & Profitability of Sawai Pharmaceutical (in USD Million), 2011-2015
  • Figure 141: Revenues & Profitability of Sun Pharmaceutical (in USD Million), 2011-2015

List of Tables

  • Table 1: Growth of the Global Generics Industry by Value (in USD Billion), 2011-2015
  • Table 2: Generics Percentage of Total Pharmaceutical Volume & Market Volume of Global Generics Industry (%), 2011-2015
  • Table 3: Global Generics Industry, Segmentation by Geography (in USD Billion), 2015
  • Table 4: Major Patent Expiries
  • Table 5: Patent Expiries for Leading Biologic Drugs, 2010-2016
  • Table 6: Regulations for Usage of Generic Drugs in Selected EU Countries
  • Table 7: Incentives for Generic Drugs in Selected EU Countries
  • Table 8: Companies Moving towards Vertical Integration
  • Table 9: Major Authorized Generics, as of 2014
  • Table 10: Value of the Generics Market in Australia (in USD Million), 2011-2015
  • Table 11: Volume Growth of the Generics Market in Australia (%), 2011-2015
  • Table 12: Share of Australia in the Asia Pacific Generics Industry (in USD Billion & %), 2015
  • Table 13: Forecast of the Generics Market in Australia (in USD Million), 2015-2020
  • Table 14: Volume Forecast of the Generics Market in Australia (%), 2015-2020
  • Table 15: Value of the Generics Market in Brazil (in USD Billion), 2011-2015
  • Table 16: Volume Growth of the Generics Market in Brazil (%), 2011-2015
  • Table 17: Share of Brazil in the Americas Generics Industry (in USD Billion & %), 2015
  • Table 18: Forecast of the Generics Market in Brazil (in USD Billion), 2015-2020
  • Table 19: Volume Forecast of the Generics Market in Brazil (%), 2015-2020
  • Table 20: Value of the Generics Market in Canada (in USD Million), 2011-2015
  • Table 21: Volume Growth of the Generics Market in Canada (%), 2011-2015
  • Table 22: Share of Canada in the Americas Generics Industry (% & USD Billion), 2015
  • Table 23: Forecast of the Generics Market in Canada (in USD Million), 2015-2020
  • Table 24: Volume Forecast of the Generics Market in Canada (%), 2015-2020
  • Table 25: Value of the Generics Market in China (in USD Billion), 2011-2015
  • Table 26: Volume Growth of the Generics Market in China (%), 2011-2015
  • Table 27: Share of China in the Asia Pacific Generics Industry (% & USD Billion), 2015
  • Table 28: Forecast of the Generics Market in China (in USD Billion), 2015-2020
  • Table 29: Volume Forecast of the Generics Market in China (%), 2015-2020
  • Table 30: Value of the Generics Market in France (in USD Billion), 2011-2015
  • Table 31: Volume Growth of the Generics Market in France (%), 2011-2015
  • Table 32: Share of France in the European Generics Industry (% & USD Billion), 2015
  • Table 33: Forecast of the Generics Market in France (in USD Billion), 2015-2020
  • Table 34: Volume Forecast of the Generics Market in France (%), 2015-2020
  • Table 35: Value of the Generics Market in Germany (in USD Billion), 2011-2015
  • Table 36: Volume Growth of the Generics Market in Germany (%), 2011-2015
  • Table 37: Share of Germany in the European Generics Industry (% & USD Billion), 2015
  • Table 38: Forecast of the Generics Market in Germany (in USD Billion), 2015-2020
  • Table 39: Volume Forecast of the Generics Market in Germany (%), 2015-2020
  • Table 40: Value of the Generics Market in India (in USD Billion), 2011-2015
  • Table 41: Volume Growth of the Generics Market in India (%), 2011-2015
  • Table 42: Share of India in the Asia Pacific Generics Industry (in USD Billion & %), 2015
  • Table 43: Forecast of the Generics Market in India (in USD Billion), 2015-2020
  • Table 44: Volume Forecast of the Generics Market in India (%), 2015-2020
  • Table 45: Value of the Generics Market in Indonesia (in USD Billion), 2011-2015
  • Table 46: Volume Growth of the Generics Market in Indonesia (%), 2011-2015
  • Table 47: Share of Indonesia in the Asia Pacific Generics Industry (in USD Billion & %), 2015
  • Table 48: Forecast of the Generics Market in Australia (in USD Billion), 2015-2020
  • Table 49: Volume Forecast of the Generics Market in Indonesia (%), 2015-2020
  • Table 50: Value of the Generics Market in Italy (in USD Million), 2011-2015
  • Table 51: Volume Growth of the Generics Market in Italy (%), 2011-2015
  • Table 52: Share of Italy in the European Generics Industry (% & USD Billion), 2015
  • Table 53: Forecast of the Generics Market in Italy (in USD Million), 2015-2020
  • Table 54: Volume Forecast of the Generics Market in Italy (%), 2015-2020
  • Table 55: Value of the Generics Market in Japan (in USD Billion), 2011-2015
  • Table 56: Volume Growth of the Generics Market in Japan (%), 2011-2015
  • Table 57: Share of Japan in the Asia Pacific Generics Industry (% & USD Billion), 2015
  • Table 58: Forecast of the Generics Market in Japan (in USD Billion), 2015-2020
  • Table 59: Volume Forecast of the Generics Market in Japan (%), 2015-2020
  • Table 60: Value of the Generics Market in Mexico (in USD Billion), 2011-2015
  • Table 61: Volume Growth of the Generics Market in Mexico (%), 2011-2015
  • Table 62: Share of Mexico in the Americas Generics Industry (in USD Billion & %), 2015
  • Table 63: Forecast of the Generics Market in Mexico (in USD Billion), 2015-2020
  • Table 64: Volume Forecast of the Generics Market in Mexico (%), 2015-2020
  • Table 65: Value of the Generics Market in the Netherlands (in USD Million), 2011-2015
  • Table 66: Volume Growth of the Generics Market in the Netherlands (%), 2011-2015
  • Table 67: Share of Netherlands in the European Generics Industry (% & USD Billion), 2015
  • Table 68: Forecast of the Generics Market in the Netherlands (in USD Million), 2015-2020
  • Table 69: Volume Forecast of the Generics Market in the Netherlands (%), 2015-2020
  • Table 70: Value of the Generics Market in Singapore (in USD Million), 2011-2015
  • Table 71: Volume Growth of the Generics Market in Singapore (%), 2011-2015
  • Table 72: Share of Singapore in the Asia Pacific Generics Industry (in USD Billion & %), 2015
  • Table 73: Forecast of the Generics Market in Singapore (in USD Million), 2015-2020
  • Table 74: Volume Forecast of the Generics Market in Singapore (%), 2015-2020
  • Table 75: Value of the Generics Market in South Africa (in USD Million), 2011-2015
  • Table 76: Volume Growth of the Generics Market in South Africa (%), 2011-2015
  • Table 77: Share of South Africa in the MEA Generics Industry (in USD Billion & %), 2015
  • Table 78: Forecast of the Generics Market in South Africa (in USD Million), 2015-2020
  • Table 79: Volume Forecast of the Generics Market in South Africa (%), 2015-2020
  • Table 80: Value of the Generics Market in South Korea (in USD Billion), 2011-2015
  • Table 81: Volume Growth of the Generics Market in South Korea (%), 2011-2015
  • Table 82: Share of South Korea in the Asia Pacific Generics Industry (in USD Billion & %), 2015
  • Table 83: Forecast of the Generics Market in South Korea (in USD Billion), 2015-2020
  • Table 84: Volume Forecast of the Generics Market in South Korea (%), 2015-2020
  • Table 85: Value of the Generics Market in Spain (in USD Billion), 2011-2015
  • Table 86: Volume Growth of the Generics Market in Spain (%), 2011-2015
  • Table 87: Share of Spain in the European Generics Industry (% & USD Billion), 2015
  • Table 88: Forecast of the Generics Market in Spain (in USD Billion), 2015-2020
  • Table 89: Volume Forecast of the Generics Market in Spain (%), 2015-2020
  • Table 90: Value of the Generics Market in the UK (in USD Billion), 2011-2015
  • Table 91: Volume Growth of the Generics Market in the UK (%), 2011-2015
  • Table 92: Share of the UK in the European Generics Industry (% & USD Billion), 2015
  • Table 93: Forecast of the Generics Market in the UK (in USD Billion), 2015-2020
  • Table 94: Volume Forecast of the Generics Market in the UK (%), 2015-2020
  • Table 95: Value of the Generics Market in the US (in USD Billion), 2011-2015
  • Table 96: Volume Growth of the Generics Market in the US (%), 2011-2015
  • Table 97: Share of the US in the Global Generics Industry (% & USD Billion), 2015
  • Table 98: Forecast of the Generics Market in the US (in USD Billion), 2015-2020
  • Table 99: Volume Forecast of the Generics Market in the US (%), 2015-2020
  • Table 100: Austria's Box Model for Reimbursement
  • Table 101: Drug Prices in Jan Aushadhi Shops in India Compared to Market Prices
  • Table 102: Reimbursement Categories of Medicines in Norway
  • Table 103: Average Retail Coinsurance Rates by Tier, (%)
  • Table 104: Global Generics Industry Forecast (in USD Billion), 2015-2020
  • Table 105: Global Generics Industry Forecast by Volume & Percentage Growth (% of Pharma Volume), 2015-2020
  • Table 106: Key Financials of Allergan Plc (in USD Million), 2010-2014
  • Table 107: Key Financials of Aspen Pharmacare (in USD Million), 2011-2015
  • Table 108: Key Financials of Cipla Limited (in USD Million), 2011-2015
  • Table 109: Key Financials of Daiichi Sankyo (in USD Million), 2011-2015
  • Table 110: Key Financials of Lupin (in USD Million), 2011-2015
  • Table 111: Key Financials of Mylan (in USD Million), 2010-2014
  • Table 112: Key Financials of PT Kalbe Farma Tbk (in USD Million), 2010-2014
  • Table 113: Key Financials of Sanofi SA (in USD Million), 2010-2014
  • Table 114: Key Financials of STADA Arzneimittel AG (in USD Million), 2010-2014
  • Table 115: Key Financials of Teva Pharmaceutical (in USD Million), 2010-2014
  • Table 116: Key Financials of Yuhan Corporation (in USD Million), 2010-2014
  • Table 117: Key Financials of Adcock Ingram (in USD Million), 2010-2014
  • Table 118: Key Financials of Aurobindo Pharma (in USD Million), 2011-2015
  • Table 119: Key Financials of China Grand Pharmaceutical and Healthcare (in USD Million), 2010-2014
  • Table 120: Key Financials of PT Indofarma (Persero) (in USD Million), 2010-2014
  • Table 121: Key Financials of Sawai Pharmaceutical (in USD Million), 2011-2015
  • Table 122: Key Financials of Sun Pharmaceutical (in USD Million), 2011-2015
Back to Top